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Abstract
Patient-derived induced pluripotent stem cells (iPSCs) have become a promising resource for 
exploring genetics of complex diseases, discovering new drugs, and advancing regenerative 
medicine. Increasingly, laboratories are creating their own banks of iPSCs derived from diverse 
donors. However, there are not yet standardized guidelines for qualifying these cell lines, i.e., 
distinguishing between bona fide human iPSCs, somatic cells, and imperfectly reprogrammed 
cells. Here, we report the establishment of a panel of 30 iPSCs from CD34+ peripheral blood 
mononuclear cells, of which 10 were further differentiated in vitro into all three germ layers. We 
characterized these different cell types with commonly used pluripotent and lineage specific 
markers, and showed that NES, TUBB3, and OTX2 cannot be reliably used as ectoderm 
differentiation markers. Our work highlights the importance of marker selection in iPSC 
authentication, and the need for the field to establish definitive standard assays.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
*Corresponding author. mwmedina@chori.org (M.W. Medina).
Author contributions
Y-LK, AM, GN and MWM conceived and designed the experiments. CI and GS recruited donors for the creation of iPSCs. AM and 
GN generated and maintained iPSC lines, and performed differentiation assays. AM performed live cell staining, and collected cell 
morphology and qPCR data. Y-LK and GN performed immunostaining and flow cytometry analyses. KES, VS, NT and MI 
contributed to the supplemental information. ANM provided fibroblast derived iPSC lines. Y-LK performed statistical analyses. Y-LK 
and MWM drafted the manuscript, with assistance from AM, GN and RMK. All authors read and approved the final manuscript.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.scr.2019.101434.
HHS Public Access
Author manuscript
Stem Cell Res. Author manuscript; available in PMC 2019 June 14.
Published in final edited form as:
Stem Cell Res. 2019 May ; 37: 101434. doi:10.1016/j.scr.2019.101434.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Human induced pluripotent stem cell; Trilineage differentiation; Ectoderm marker; NESTIN; 
PAX6
1. Introduction
Patient-derived induced pluripotent stem cells (iPSCs) retain the genetic characteristics of 
the donor, exhibit self-renewal, and can be cryopreserved and differentiated into disease-
relevant tissue types. These capabilities render iPSCs a highly versatile cellular model 
enabling a wide range of research studies and experimental designs. For examples, these 
cells may be used for identifying transcriptomic and metabolomic markers of drug efficacy, 
screening in drug discovery, and advancing regenerative medicine (Avior et al., 2016; 
Sterneckert et al., 2014).
iPSCs are reprogrammed from somatic cells through the ectopic expression of defined 
transcription factors such as POU5F1 (aka OCT4), SOX2, KLF4, and c-MYC (also known 
as the Yamanaka factors) (Takahashi and Yamanaka, 2006). Since the process of 
reprogramming may be incomplete, thus generating heterogeneous cell populations, it is 
essential to validate the quality of iPSC lines generated, and to distinguish bona fide iPSCs 
from partially reprogrammed cells (Chan et al., 2009). This interrogation includes 
confirming expression of pluripotency factors, for example POU5F1 or TRA-1–60, and also 
displaying the ability to differentiate into the three germ layers: endoderm, mesoderm, and 
ectoderm (Chan et al., 2009). Demonstration of germ layer differentiation has traditionally 
been performed through a teratoma assay, in which cells considered to be pluripotent would 
be injected into an immunocompromised mouse, and tested for their ability to create a 
teratoma with cells from all three germ layers. However, as this assay is labor intensive, 
costly and time-consuming, in vitro trilineage differentiation, in which specialized media is 
used to induce lineage-directed differentiation, has become a highly popular alternative 
(Buta et al., 2013; Vallier et al., 2009).
A wide range of markers has been reported in the literature to be indicative of the three germ 
layers. Commonly used endoderm markers include SOX17 (Kanai-Azuma et al., 2002), 
FOXA2 (Burtscher and Lickert, 2009), CXCR4 (D’Amour et al., 2005), and GATA4 
(Fujikura et al., 2002). NCAM1 (Evseenko et al., 2010) and TBXT (aka brachyury) 
(Wilkinson et al., 1990) are often used as mesoderm markers. NES (nestin) (Lendahl et al., 
1990) and PAX6 (Zhang et al., 2010) are among the most commonly used markers for 
ectoderm differentiation. Here we report that several of the ectoderm markers commonly 
used during validation studies are not specific to ectoderm as there is a high degree of 
staining in undifferentiated iPSCs derived from CD34+ peripheral blood mononuclear cells 
(PBMCs). These studies highlight the need for further development of iPSC validation 
protocols.
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2. Materials and methods
2.1. Donors and samples
The iPSCs used to obtain data reported here were generated as part of the 
Pharmacogenomics of Statin Therapy (POST) Center within the Pharmacogenomics 
Research Network. Blood samples were drawn from donors recruited at Kaiser Permanente 
Northern California (Table 1). Written informed consent was obtained from all study 
subjects, and studies were performed in accordance with all relevant regulatory guidelines. 
This study was approved by the IRBs at Kaiser Permanente Northern California and the 
UCSF Benioff Children’s Hospitals.
2.2. PBMC isolation
After 1:1 dilution in Dulbecco’s Phosphate Buffered Saline containing 2% Fetal Bovine 
Serum (FBS, Omega Scientific, Cat. # FB-02, Lot # 8462) whole blood from each donor was 
layered over a Ficoll-Pacque gradient (Fisher Scientific, Cat. # 45001750) in SepMate-50 
tubes (StemCell Technologies, Cat. # 85460) and centrifuged at 1200 ×g for 20 min. PBMCs 
were decanted into a separate tube, washed in PBS supplemented with 2% FBS, and 
centrifuged for an additional 10 min at 500 × g. PBMC were resuspended in RPMI 
supplemented with 20% FBS and 10% DMSO, and cryopreserved in liquid nitrogen.
2.3. iPSC generation
PBMC aliquots were thawed and resuspended in StemSpan SFEM II expansion media 
(StemCell Technologies, Cat. # 09605) with CD34+ expansion supplement (StemCell 
Technologies, Cat. # 02691). Cells were seeded into an Ultra-Low Attachment 6-well plate 
(Corning, Cat. # 3471). After 6 days, the CD34+ cells were counted and up to 1 million cells 
were reprogrammed using a combination of plasmids purchased from Addgene encoding for 
POU5F1, and shRNA for TP53 (ID: 27077) SOX2, and KLF4 (ID: 27078), L-MYC, and 
LIN28(ID: 27080), and EBNA1(ID: 37624) (Okita et al., 2013). Cells were transfected using 
program U-008 on the Lonza Nucleofector 2B device (Lonza, Cat. # AAB-1001), seeded 
onto mitomycin C treated SNL feeder cells (Applied StemCel,l Cat. # ASF-1327) in SFEM 
II media plus CD34+ Expansion supplement, and fed every other day with mTeSR1 
(StemCell Technologies, Cat. # 85850) until colony establishment.
2.4. iPSC culture
iPSCs were harvested from SNL feeder plates using Magnetic Activated Cell Sorting 
(MACS) via positive selection for TRA-1–60 surface pluripotency marker (Miltenyi Biotec, 
Cat. # 130-100-832). iPSCs were seeded at roughly 200,000 cells/well onto 6-well plates 
coated with Cultrex reduced growth factor basement membrane (Trevigen, Cat. # 
3533-001-02). Cells were fed daily with 1.5 mL of mTeSR1 and passaged when 
approximately 80% confluent using ReLeSR (StemCell Technologies, Cat. # 05872), which 
leaves behind differentiated cells.
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2.5. Live cell staining
Alkaline Phosphatase detection was executed using the Alkaline Phosphatase Live Stain kit 
(Life Technologies, Cat. # A14353) according to manufacturer’s instructions. Cells were 
visualized using a Keyence BZ-X700 series microscope. SSEA-4 detection was carried out 
using the StainAlive SSEA-4 mouse anti-human antibody (Reprocell, Cat. # 09–0097). 
Antibody was diluted 1:200 in mTeSR1 and cells were incubated in antibody containing 
medium for 30 min in standard culture conditions. The staining medium was removed and 
the cells washed gently 2 times with mTeSR1. Fresh media was added and the cells were 
visualized using a Keyence BZ-X700 series microscope.
2.6. iPSC characterization
Karyotype analysis was performed by the Cedars Sinai RMI iPSC Core. PluriTest and 
KaryoStat assays were performed by Thermo Fisher Scientific.
2.7. Cellular differentiation assay
Ten iPSC lines underwent in vitro directed differentiation in four independent experiments 
with 1 to 4 lines in each batch. Cells were seeded onto 12-well plates coated with Cultrex at 
400,000 cells/well for both the ectoderm and endoderm conditions and 100,000 cells/well 
for the mesoderm condition and treated the appropriate differentiation media using the 
STEMdiff Trilineage Differentiation Kit (StemCell Technologies, Cat. # 05230) according to 
manufacturer instructions. Differentiated cells were then collected for RNA isolation or 
fixed with 4% paraformaldehyde for immunostaining.
2.8. Immunostaining and flow cytometry analyses
80% confluent cells were detached from the plates into single cell suspension using 
Accutase (StemCell Technologies, Cat. # 07920). Cells were washed in DPBS, then fixed 
with 4% paraformaldehyde in PBS and incubated for 15 min. Fixed cells were washed with 
DPBS, resuspended with DPBS+1%BSA, and stored at 4 °C for up to 7 days prior to 
analysis. For intracellular markers, fixed cells were treated with Permeabilization Buffer 
(eBioscience, Cat. # 00-8333-56). Cells were transferred to Falcon 96-well V bottom plates 
(Fisher Scientific, Cat. # 08772212) for immunostaining. Antibody incubations were 
performed on ice in the dark for 45 min in 100 ul/well of CAS-Block (Thermo Fisher 
Scientific, Cat. # 008120) supplemented with 1% BSA and 5% goat serum (plus 0.2% Triton 
for intracellular markers). Cells were then washed twice with 200 ul/well DPBS (cell surface 
markers) or Permeabilization Buffer (intracellular markers) before resuspended in 100 ul/
well DPBS +1% BSA. Flow cytometry analysis was performed on the BD LSRFortessa with 
a High Throughput Sampler, with markers quantified in 9000 gated events on average. The 
antibodies used for detecting iPSC, endoderm, mesoderm, and ectoderm markers, as well as 
corresponding isotype controls, are listed in Table 2.
2.9. qPCR
RNA was isolated via QIAcube (serial number: 50946) and RNeasy Mini Kit protocol 
“Purification of total RNA from 5 × 106 − 1 × 107 animal cells (with QIAshreddder 
homogenization)” (Firmware Version FIW-50–001-J_FW_MB.hex and program version 
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FIW-50–002-G_PLC_MB.prs or higher) following manufacturer’s instructions. cDNA was 
synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosysystems, Cat. # 4368814) according to manufacturer’s instructions. Quantitative PCR 
with the Taqman™ primers POU5F1 (Thermofisher, Cat. # 4448892), PAX6 (Thermofisher, 
Cat. # 4448892), NES (Thermofisher, Cat. # 4448892), TUBB3 (Thermofisher, Cat. # 
4448892), and OTX2 (Thermofisher, Cat. # 4448892) was carried out by a liquid handling 
robotic system and run via Quantstudio 12K Flex (serial number: 285880333).
2.10. Statistical analysis
Two-tailed paired t-tests were used to determine statistically significant differences between 
cell types. Analyses were performed using GraphPad Prism 7.
3. Results
3.1. Generation and validation of blood-derived human iPSCs
The CD34+ PBMC isolated from 30 individuals were nucleofected by episomal vectors 
expressing POU5F1, SOX2, KLF4, L-MYC, LIN28, EBNA1, and shRNA for TP53 (Okita 
et al., 2013). This integration-free approach minimizes genetic manipulation of the iPSCs. 
After emergence of colonies with distinct iPSC morphology (i.e. embryonic stem cell-like 
compact colonies comprised of cells with large nuclei and well-defined borders (Chan et al., 
2009)), TRA-1–60 expressing cells were selected using Magnetic Activated Cell Sorting 
(MACS) to obtain one iPSC line per donor in a pooled culture (Yang et al., 2015). Compared 
to clonally derived iPSCs, this method has been shown to be more efficient, potentially 
better standardized, and less variable than clonal selection.
To confirm the identity of the established iPSC lines, colonies were subject to live staining 
of alkaline phosphatase (AP, Fig. 1A) or SSEA-4 expression (Fig. 1B). In addition, 
expression of pluripotency markers POU5F1 and TRA-1–60, and the differentiation marker 
SSEA-1, were quantified by immunostaining and flow cytometry in all 30 iPSC lines. Of the 
cells within an individual line, 91.3% (range 73.2–96.9%) were positive for POU5F1 
expression, 93.3% (range 77.6–98.9%) were positive for TRA-1–60, and 2.7% (range 0.2–
4.9%) were positive for SSEA-1 (Fig. 1C and S1). All lines were > 90% positive for 
POU5F1 and/or TRA-1–60, and < 5% were positive for SSEA-1. Karyotype analyses of 
three representative lines showed no genetic abnormalities (Fig. 1D). Five iPSC lines 
(including 3 of the 10 lines underwent in vitro trilineage differentiation) were also tested by 
PluriTest and KaryoStat, and all of them were found to be pluripotent with no chromosomal 
aberrations (Fig. S2).
3.2. Validation of iPSCs via in vitro trilineage differentiation
Next, to confirm the pluripotency of the iPSC lines, we performed a trilineage differentiation 
assay on 10 lines using the STEMdiff Trilineage Differentiation kit. To authenticate 
generation of each lineage, endoderm differentiated cells were stained for SOX17 and 
FOXA2, mesoderm cells were stained for NCAM1, and ectoderm cells were stained for 
NES, with the degree of immunostaining quantified by flow cytometry. Matched iPSCs, 
from whom the differentiated cells were derived, were also stained for lineage specific 
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markers as negative controls. After differentiation, cellular morphology was dramatically 
altered from the typical iPSC phenotype, Fig. S3. Importantly, after directed endoderm 
differentiation, we found evidence of both SOX17 and FOXA2 positive cells in each of the 
10 lines tested, with on average46.3% (range 10–75.7%) of cells/line expressing SOX17, 
and 45.3% (range 14.8–68.9%) of cells/line expressing FOXA2 (Fig. 2A and Fig. S4). On 
average 84% (range 26.6–99.5%) of cells/line were NCAM1 positive after directed 
mesoderm differentiation (Fig. 2A and Fig. S4). For both the endoderm and mesoderm 
markers, we observed little to no staining of the undifferentiated iPSC lines (2.0% positive 
cells/marker/line on average).
After directed differentiation into ectoderm, we observed a high degree of NES positive cells 
(90%, range 62.2–99.2% positive cells/line). However, surprisingly a similar number of NES 
positive cells were also detected in the undifferentiated iPSCs (96.5%, range 89.6–98.7% 
positive cells/line). To test the consistency of this result, we repeated the analysis using a 
second antibody against NES that was derived from a different clone, and found similarly 
very high levels of NES positive cells/line in both the ectoderm and undifferentiated iPSC 
lines (Fig. 2A and Fig. S4). Since NES is a commonly used ectoderm marker, we performed 
a verification study in which an independent lab tested NES expression in an independent 
iPSC line before and after ectoderm differentiation using several NES antibodies. Again, the 
undifferentiated iPSC line had > 80% NES positive cells/line, with the degree of staining 
indistinguishable between the differentiated and undifferentiated cells (Fig. S5).
Based on these results, we next sought to test whether other commonly reported ectoderm 
markers may have similar non-specific staining patterns. Since the ectoderm differentiation 
medium tested creates neuroectoderm like cells, we assessed TUBB3 (aka TUJ1), OTX2, 
and PAX6. Similar to our observations with NES, we found high levels of TUBB3 and 
OTX2 positive cells in iPSC lines before and after differentiation, with no difference in their 
levels between the iPSC and ectoderm lines (Fig. 2A and Fig. S4). In contrast, while the 
number of PAX6 positive cells/line was relatively low (12.2%, range 0.7–40.9%) after 
ectoderm directed differentiation, it was statistically significantly higher than in the 
undifferentiated iPSC lines (0.1%, range 0–0.9%, p = .03). We confirmed our findings by 
performing co-immunostaining of the pluripotency marker POU5F1 with either NES, 
TUBB3, OTX2, or PAX6 in undifferentiated iPSCs. While pluripotent iPSCs (i.e. POU5F1 
positive cells) express various levels of NES, TUBB3, and OTX2 protein, we found no 
detectable PAX6 expression (Fig. 2B and Fig. S6).
In the absence of a robust ectoderm-specific marker, to validate that the ectoderm directed 
differentiation was successful at yielding the expected cell type, we performed qPCR of 
POU5F1 and the four commonly used ectoderm markers we tested. Transcript levels of 
pluripotent marker POU5F1 are known to be reduced after ectoderm differentiation (Daily et 
al., 2017), and as expected, these were reduced by 92 ± 2% (P < .001) (Fig. 2C). Of the four 
candidate ectoderm markers (NES, TUBB3, OTX2, and PAX6), we found significantly 
elevated expression levels of OTX2 (11.6 ± 2.6 fold increase, P < .0001) and PAX6 (1143.5 
± 592.5 fold increase, P < .0001) after ectoderm differentiation (Fig. 2D). To ensure that the 
expression profile was not impacted by the cell type the iPSCs were originated from, we 
examined our RNAseq data from six fibroblasts-derived and two CD34+ cell-derived iPSC 
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lines and found comparable expression levels of markers selected for self-renewal and 
ectoderm (Fig. S7).
4. Discussion
The use of iPSC lines in biomedical research has increased exponentially in recent years. 
However, as this technology remains under development, the lack of standardized guidelines 
for validating whether newly established human iPSCs are bona fide lines remains a 
challenge in the field. For example, while teratoma assays were once considered the gold 
standard for authenticating new lines, recent studies have called into question whether these 
time-consuming and expensive as-says are still necessary (Buta et al., 2013). In addition, 
while traditional iPSC lines were established from fibroblasts derived from skin biopsies, 
more recently generation of iPSC lines from blood derived cells has grown in popularity due 
to the ease of primary cell isolation. Here, we report that during authentication of a newly 
established iPSC repository generated from blood derived cells, we discovered that many of 
the commonly used markers for ectoderm show high levels of expression in undifferentiated 
iPSC lines.
Using cell lines from 10 donors, we found comparable levels of NES, TUBB3, and OTX2 in 
iPSCs with and without differentiation. For NES specifically (one of the most commonly 
reported ectoderm markers), we tested multiple antibodies in multiple cell lines across two 
independent laboratories, and found similar high degrees of staining in the undifferentiated 
state. Based on these findings, we conclude that NES, TUBB3 and OTX2 are not ectoderm 
specific markers. Notably, NES and OTX2 are currently recommended in the STEMDiff 
Trilineage Differentiation Kit and Human Pluripotent Stem Cell Functional Identification 
Kit (R&D Systems) as ectoderm markers, respectively.
Although we failed to identify a difference in NES transcript levels between undifferentiated 
iPSCs and differentiated ectoderm cells, Hoffman et al. (2017) previously reported that NES 
transcript levels are elevated in neural progenitor cells (NPCs) compared to undifferentiated 
iPSCs, suggesting that NES may be a suitable neuroectoderm marker. Notably, NPCs are at 
a more differentiated state compared to the ectoderm that we characterized here. Through 
NES immunocytochemistry of iPSCs and NPCs we found that iPSCs do express detectable 
level of NES protein, but to a much lower extent than NPCs (Fig. S8). Thus, when using 
relatively insensitive methods such as immunohistochemistry, this difference in expression 
levels may be leveraged to enable use of NES expression as a NPC marker. However, flow 
cytometry is substantially more sensitive and quantitative compared to 
immunocytochemistry, and in particular, is able to distinguish even low levels of NES signal 
compared to an IgG incubated control. Based on our findings, investigators should avoid 
NES as an ectoderm marker when using immunostaining and flow cytometry to access 
trilineage differentiation efficiency. Furthermore, care is advised if using NES as a 
neuroectoderm marker.
In the case of TUBB3, RNAseq data made available by Daily et al. also shows no evidence 
of increased transcript levels in ectoderm differentiated cells compared to stem cell lines 
(Daily et al., 2017). These findings are consistent with our results indicating that while 
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TUBB3 is widely used as a marker for neuronal differentiation, it is not suitable as an 
ectoderm marker in iPSC trilineage validation studies.
Interestingly, we found that while OTX2 transcript levels were significantly upregulated 
after ectoderm differentiation, the degree of cell surface protein expression in the 
undifferentiated iPSCs rendered this protein non-useful as an ectoderm marker. Thus, 
validation of new markers at the protein level must be tested irrespective of whether 
differences are observed at the mRNA level.
Of the markers tested, PAX6 was the only ectoderm marker that showed increased 
expression in the differentiated versus undifferentiated cells. While the overall percent 
positive cells/line was relatively low, consistent with the wide range of differentiation 
capacity reported among iPSCs (Carcamo-Orive et al., 2017; Kajiwara et al., 2012; Kilpinen 
et al., 2017; Kyttala et al., 2016), it is possible that with further modification to the protocol, 
such as changing cell seeding density, greater staining could be obtained. In addition, it has 
been reported that further differentiating the cells from ectoderm to NPCs using SMAD 
signaling pathway inhibitors increases NES and PAX6 transcript and protein levels 
(Chambers et al., 2009; Hoffman et al., 2017).
A caveat of our study is that we only rigorously tested trilineage differentiation using the 
STEMdiff Trilineage Differentiation Kit. Thus, it would be of interest to assess whether 
other commercially available kits and reported protocols yield similar results.
In summary, we have shown that NES, TUBB3, and OTX2 cannot be reliably used as 
ectoderm differentiation markers when flow cytometry is utilized for measurement. These 
findings also highlight the importance of including relevant negative controls during 
validation studies. Investigators should be cautious in selecting markers until definitive 
standard assays for iPSC pluripotency are established.
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Fig. 1. 
Validation of blood-derived human iPSCs. Live stain of representative iPSC colonies 
showing A) alkaline phosphatase activity, and B) SSEA-4 expression. C) Flow cytometry 
analysis of pluripotency markers POU5F1 and TRA-1–60, and differentiation marker 
SSEA-1 in iPSCs (mean ± SD, n = 30). See also Fig. S1 for flow cytometry data on isotype 
controls. D) Karyotype analysis of three iPSC lines showed normal chromosomal content. 
See also Fig. S2 for additional characterization of pluripotency marker expression and 
genomic aberrations.
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Fig. 2. 
Expression of trilineage differentiation markers. A) Matched iPSCs and differentiated 
endoderm, mesoderm, ectoderm cells were analyzed by immunostaining followed by flow 
cytometry for expression of markers specific for each germ layer (mean ± SEM, n = 7–10 
cell lines). See also Fig. S1 for isotype control data, Fig. S3 for morphological changes after 
differentiation, Fig. S4 for paired data, and Fig. S5 for independent validation of iPSC NES 
staining. B) Representative flow cytometry plots showing co-immunostaining of 
pluripotency marker POU5F1 with each of the four candidate ectoderm markers in 
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undifferentiated iPSCs. See also Fig. S6 for complete dataset. C, D) Expression of 
pluripotent marker POU5F1 (C) and four candidate ectoderm markers (D) quantified by 
qPCR in matched iPSCs and ectoderm differentiated cells (mean ± SEM, n = 8). Gene 
expression is shown as fold change of ectoderm differentiated cells compared to iPSCs, with 
dotted line indicating fold change of 1. * P < .05, *** P < .001, **** P < .0001, two-tailed 
paired t-tests.
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Table 1
Demographics of blood donors.
n %
Total 30 100
Gender
 Female 18 60
 Male 12 40
Race/Ethnicity
 White 23 76.7
 Black or African American 3 10
 Asian 4 13.3
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